Abstract
Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.
Keywords: cAMP, Cognitive Impairment, Depression, Phosphodiesterase, inhibitors, Schizophrenia.
Current Topics in Medicinal Chemistry
Title:Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders
Volume: 16 Issue: 29
Author(s): Ana M. Garcia, Ana Martinez and Carmen Gil
Affiliation:
Keywords: cAMP, Cognitive Impairment, Depression, Phosphodiesterase, inhibitors, Schizophrenia.
Abstract: Phosphodiesterases (PDEs) have gained attention as potential pharmacological targets for neuropsychiatric diseases due to their ability to hydrolyze the second messengers, cGMP and/or cAMP. It is well-known the relationship between cAMP signaling and inflammation. Since neuroinflammation is considered to play an important role in the pathology of brain disorders, inhibition of PDEs highly expressed in brain has emerged as an innovative strategy for the treatment of these pathologies. PDE4, 7, 8 and 10 inhibitors are presented here as promising drug candidates to overcome the partial efficacy and adverse effects of the current therapy for neuropsychiatric illness such as depression, cognitive impairments or schizophrenia. Enhancing the intracellular concentration of cAMP underlies the effects of PDE inhibitors in the above mentioned disorders.
Export Options
About this article
Cite this article as:
Garcia M. Ana, Martinez Ana and Gil Carmen, Enhancing cAMP Levels as Strategy for the Treatment of Neuropsychiatric Disorders, Current Topics in Medicinal Chemistry 2016; 16 (29) . https://dx.doi.org/10.2174/1568026616666160426151306
DOI https://dx.doi.org/10.2174/1568026616666160426151306 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Facts and Fiction: Cellular Models for High Throughput Screening for HIV-1 Reactivating Drugs
Current HIV Research Plasma Amyloid-β Oligomers and Soluble Tumor Necrosis Factor Receptors as Potential Biomarkers of AD
Current Alzheimer Research Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research Genetic Studies in Relation to Kuru: An Overview
Current Molecular Medicine Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Graphical Abstracts:
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Current Neuropharmacology Potential Therapeutic Relevance of CRISPR/Cas9 Guided Epigenetic Regulations for Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry Catatonia in Affective Disorders
Current Psychiatry Reviews Attention Deficit and Hyperactivity Disorder: Controversies of Diagnosis and Safety of Pharmacological and Nonpharmacological Treatment
Current Drug Safety Dipeptidyl Peptidase-4 (CD26): Knowing the Function before Inhibiting the Enzyme
Current Medicinal Chemistry Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal and Human Studies
Current Pharmaceutical Design Herbal Medication and Nutraceuticals for the Management of Anxiety and Depression
Current Psychopharmacology The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Acknowledgements to Reviewers
Current Alzheimer Research Anabolic Steroid - and Exercise - Induced Cardio-Depressant Cytokines and Myocardial β1 Receptor Expression in CD1 Mice
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member:
Central Nervous System Agents in Medicinal Chemistry